9780 Medical Center Drive
About GlycoMimetics, Inc.
GlycoMimetics is an oncology-focused biotechnology company. We are dedicated to improving the lives of patients by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates.
Our management team consists of industry leaders with deep experience in the pharmaceutical/biotech industry.
Since our inception, we have developed a diversified product pipeline. Today, the company’s proprietary investigational drug for acute myeloid leukemia (AML) is being evaluated in two pivotal Phase 3 clinical trials.
229 articles with GlycoMimetics, Inc.
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that Chief Executive Officer Rachel King will provide a company overview at the Jefferies 2021 Virtual Healthcare Conference. Ms. King’s presentation will take place from 2:30 to 2:55 p.m. on June 3, 2021.
GlycoMimetics Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplantation
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians at Washington University School of Medicine in St. Louis have dosed the first patient in an investigator-sponsored trial (IST) evaluating uproleselan as a prophylactic agent to reduce gastrointestinal (GI) toxicities associated with high-dose melphalan in cell transplantation
GlycoMimetics continues to target year-end 2021 for completing enrollment of the Company-sponsored pivotal trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML)
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Monday, May 3, 2021, at 8:30 a.m. ET.
Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 Meeting
Preclinical research included in poster supports clinical findings and demonstrates enhanced immune response in metastatic breast carcinoma model
GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model
Study demonstrates GMI-1757’s impact on immune cell infiltration and improvement of anti-PD-L1 therapeutic activity
GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the interim analysis of a Phase 1b proof-of-concept study of GMI-1359, the Company’s dual antagonist of E-selectin and CXCR4, has been accepted for presentation at the American Association of Cancer Research (AACR) 2021 Annual Meeting
Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML
GlycoMimetics (Nasdaq: GLYC) today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). In February of this year, Apollomics initiated two Phase 1 study sites in Greater China.
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020 Second half of 2021 remains the target for completion of enrollment of the GlycoMimetics-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML)
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that executives from the Company plan to participate in three virtual healthcare conferences in March.
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report fourth quarter and year-end 2020 financial results on Tuesday, March 2, 2021, at 8:30 a.m. ET.
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer.
Female leaders in the biopharma industry may further promote diversity and inclusion at the workplace and serve as role models for young female professionals. Here is a list of 16 of the highest-paid female CEOs in biopharma.
GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model
Oral presentation at 62nd ASH Annual Meeting and Exposition points to potential role for uproleselan as foundational therapy in acute myeloid leukemia (AML)
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that CEO Rachel King plans to present an overview of the company at the upcoming Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19. Both presentations will be available on the Company’s website, under the Investors tab. Details are as follows: Stifel 2020 Virtual Healthc
Enrollment in the Company-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) continues on track, and the Company reiterates its prior guidance that completion of enrollment for the Company-sponsored Phase 3 trial is expected in the second half of 2021
GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that three abstracts including data from the Company’s clinical and research portfolio have been accepted for oral presentations and two abstracts have been accepted for poster presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually December 5-8, 2020.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its third quarter financial results on Friday, November 6, 2020, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 3073766. Participants are encouraged to connect 15 minutes in advance
New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting
Data highlight the importance of early intervention with fast-acting E-selectin inhibitors to disrupt the underlying inflammatory mechanisms driving acute vaso-occlusive crisis (VOC) - Abstracts for two of GlycoMimetics’ wholly-owned product candidates, rivipansel and GMI-1687, accepted for poster and oral presentations ROCKVILLE, Md.--( BUSINESS WIRE )-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that new post hoc analyses of the
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13 th Clinical Trials on Alzheimer's Disease (CTAD) Conference